00:07 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Cell culture and mouse studies suggest modulating SF3B1-mediated splicing alone or in combination with BCL-2 and Bcl-XL inhibitors could help treat MCL1-dependent NSCLC. In three human MCL1-dependent NSCLC cell...
22:58 , Nov 14, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer; prostate cancer Cell culture and mouse studies suggest Bcl-XL inhibitors could help treat glioma, prostate and other cancers harboring the IDH1 R123H mutation. In human glioma and prostate cancer cell lines, cells...